Age
U.S. Patent and Trade
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a credit-tran of inform

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10006909			
	Filing Date		2001-12-06			
First Named Inventor Keas		Keas	ling			
	Art Unit		1652			
	Examiner Name	C. Fr	onda			
	Attorney Docket Number		BERK-036			

			Remove				
Examiner Initial*	r Cite No Patent Number		Kind Code <sup>1</sup> Issue Date Name of Patentee of cited Document		Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant Appear
	1	6495354 2002-12-17 Chappell ot al.					
	2	6531303		2003-03-11	Akrion Life Sciences LLC		
	3	6916972		2005-07-12	Falco et al.		
	4	6989257		2006-01-24	DSM IP Assets B.V.		
If you wis	to ac	dd additional U.S. Pater	t citatio	n information p	lease click the Add button.		Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove
		Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant Appear	
1 20040029239 <b>2004-02-12 Toyo</b>		Toyota Jidosha Kabushiki Kaisha		-			
	2	20040063182		2004-04-01	Toyota Jidosha Kabushiki Kaisha		

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Filing Date First Named II Art Unit Examiner Nar

Application Number		10006909
Filing Date		2001-12-06
First Named Inventor Keas		ling
Art Unit		1652
Examiner Name C. Fr		onda
Attorney Docket Number		BERK-036

	3	20050266518		2005-1	2-01	DSM IP Asset	ts B.V.					
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	please click the Add	buttor	n. Add			
	FOREIGN PATENT DOCUMENTS Remove											
Examiner Initial*	Cite No			Kind Code4	Publication Date	Name of Patentee Applicant of cited Document	or	where Rel	or Relevant	TS		
	1	WO0001650	wo			2005-01-13	DCV, inc.					
	2	WO02099095	wo			2002-12-12	Berry et al.					
	3	WO0210398	wo			2002-02-07	Hahn et al.					
	4	1360300	EP			2003-11-12	Hahn et al.					
	5	1392624	EP			2004-03-03	Berry et al.					
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add			
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove			
Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andorc country where publisher.										T5		
	National Science Foundation Award Abstract Number 9911463											
If you wis	h to a	dd additional non-paten	t literatu	re docu	ment cit	ation informat	ion please click the	Add b	utton Ac	ld		

	Application Number		10006909	
NEODIATION DIOCI COURT	Filing Date		2001-12-06	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Keas		sling	
( Not for submission under 37 CFR 1.99)	Art Unit		1652	
· · · · · · · · · · · · · · · · · · ·	Examiner Name C. Fr		onda	
	Attorney Docket Numb	er	BERK-036	

	EXAMINER SIGNATURE		
Examiner Signature		Date Considered	
*EXAMINER: Initial if citation if not in confo			

1 See Kin Codes of USPTO Patent Documents at www.USPTO\_GGV or MPEP 901.04. 2 Exter of thick that issued the document, by the two-lefter pated (WIPO Standard ST3.) 3 "For disputement pated counters, the endoated on the year of the register or surpressed the sense included in the pated document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST1.6 if possible, "Applicant is to place a check mark here if English language the resistation is attached."

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10006909
Filing Date		2001-12-06
First Named Inventor Keas		ling
Art Unit		1652
Examiner Name C. Fro		onda
Attorney Docket Number		BERK-036

#### CERTIFICATION STATEMENT

Please see	37	CFR	1 97	and	1.98 to	make the	e appropriate	selection/s	s)

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(a)(1).

OR

That no item of information contained in the information disclosure statement, was cited in a communication from a design parter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Paula A. Borden/	Date (YYYY-MM-DD)	2006-05-30
Name/Print	Paula A. Borden	Registration Number	42344

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.231.1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issuand patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.